A.R. Abdul Razak

1.0k total citations
26 papers, 760 citations indexed

About

A.R. Abdul Razak is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, A.R. Abdul Razak has authored 26 papers receiving a total of 760 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 3 papers in Surgery. Recurrent topics in A.R. Abdul Razak's work include Cancer Immunotherapy and Biomarkers (6 papers), CAR-T cell therapy research (5 papers) and Sarcoma Diagnosis and Treatment (4 papers). A.R. Abdul Razak is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), CAR-T cell therapy research (5 papers) and Sarcoma Diagnosis and Treatment (4 papers). A.R. Abdul Razak collaborates with scholars based in Canada, United States and United Kingdom. A.R. Abdul Razak's co-authors include Lillian L. Siu, Philippe L. Bédard, Aaron R. Hansen, Tom Wei‐Wu Chen, Peter J. McKenna, W.T. McNicholas, Andrew E. Russell, Awori J. Hayanga, Sébastien J. Hotte and Jeffrey R. Infante and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

A.R. Abdul Razak

26 papers receiving 749 citations

Peers

A.R. Abdul Razak

ONCOL

PRM

IMMUN

PHYSI

Marco Siano Switzerland

Masayuki Iwazaki Japan

Álvaro Pinto Spain

Takaaki Tokito Japan

Norikazu Matsuo Japan

Charlotte Domblides France

Annamaria Molino Italy

Catalina Vadell Spain

Capucine Baldini France

Irving Taylor United Kingdom

Marco Siano Switzerland

A.R. Abdul Razak

297 ×0.7

ONCOL

153 ×0.5

PRM

175 ×0.8

48 ×0.5

IMMUN

73 ×0.9

PHYSI

Citations per year, relative to A.R. Abdul Razak A.R. Abdul Razak (= 1×) peers Marco Siano

Countries citing papers authored by A.R. Abdul Razak

Since Specialization

Citations

This map shows the geographic impact of A.R. Abdul Razak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.R. Abdul Razak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.R. Abdul Razak more than expected).

Fields of papers citing papers by A.R. Abdul Razak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.R. Abdul Razak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.R. Abdul Razak. The network helps show where A.R. Abdul Razak may publish in the future.

Co-authorship network of co-authors of A.R. Abdul Razak

This figure shows the co-authorship network connecting the top 25 collaborators of A.R. Abdul Razak. A scholar is included among the top collaborators of A.R. Abdul Razak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.R. Abdul Razak. A.R. Abdul Razak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khaki, Ali Raza, Alexander I. Spira, A.R. Abdul Razak, et al.. (2024). 1706P Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multi-center multi-country phase I/IIa expansion cohort. Annals of Oncology. 35. S1023–S1023. 1 indexed citations

Razak, A.R. Abdul, et al.. (2020). Immunotherapy in Soft-Tissue Sarcoma. Current Oncology. 27(11). 17–23. 76 indexed citations

Powderly, John D., Toshio Shimizu, Patricia LoRusso, et al.. (2020). 596TiP Phase I first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumours. Annals of Oncology. 31. S499–S499. 2 indexed citations

Kanjanapan, Yada, Daphne Day, Marcus O. Butler, et al.. (2018). Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. European Journal of Cancer. 107. 1–7. 51 indexed citations

Ott, Patrick A., Y-J. Bang, A.R. Abdul Razak, et al.. (2017). Relationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028). Annals of Oncology. 28. v22–v22. 5 indexed citations

Shepshelovich, Daniel, et al.. (2017). Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database. Investigational New Drugs. 36(5). 933–938. 8 indexed citations

Shepshelovich, Daniel, et al.. (2017). Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications. Investigational New Drugs. 35(6). 827–833. 7 indexed citations

Jankú, Filip, A.R. Abdul Razak, Michael S. Gordon, et al.. (2017). Encouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST). Annals of Oncology. 28. v521–v521. 6 indexed citations

Prawira, Amy, Paul Dufort, Aaron R. Hansen, et al.. (2016). Development of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). Annals of Oncology. 27. vi330–vi330. 5 indexed citations

10.

Grilley‐Olson, Juneko E., Philippe L. Bédard, Angelica Fasolo, et al.. (2016). A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. Investigational New Drugs. 34(6). 740–749. 64 indexed citations

11.

Chen, Tom Wei‐Wu, A.R. Abdul Razak, Philippe L. Bédard, Lillian L. Siu, & Aaron R. Hansen. (2015). A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Annals of Oncology. 26(9). 1824–1829. 187 indexed citations

12.

Bièche, Ivan, Xavier Paolettí, Marie Alt, et al.. (2015). Designs of preoperative biomarkers trials in oncology: a systematic review of the literature. Annals of Oncology. 26(12). 2419–2428. 12 indexed citations

13.

Loong, Herbert H., Eric Winquist, John Waldron, et al.. (2014). Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx. European Journal of Cancer. 50(13). 2263–2270. 10 indexed citations

14.

Razak, A.R. Abdul, Denis Soulières, Scott A. Laurie, et al.. (2012). A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Annals of Oncology. 24(3). 761–769. 82 indexed citations

15.

Díaz-Padilla, Iván, Lillian L. Siu, A.R. Abdul Razak, et al.. (2012). A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. British Journal of Cancer. 107(4). 604–611. 10 indexed citations

16.

Razak, A.R. Abdul, Sébastien J. Hotte, Lillian L. Siu, et al.. (2011). Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. British Journal of Cancer. 104(5). 756–762. 52 indexed citations

17.

Burris, H. A., Jordi Rodón, A.R. Abdul Razak, et al.. (2011). Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.. Journal of Clinical Oncology. 29(15_suppl). 3043–3043. 19 indexed citations

18.

Razak, A.R. Abdul, Lillian L. Siu, Andrew K. Chan, et al.. (2011). Neurocognitive function (NCF) in patients (pts) treated with chemo/bio-radiotherapy (C/B-RT) for head and neck cancers (HNC).. Journal of Clinical Oncology. 29(15_suppl). 5522–5522. 3 indexed citations

19.

Byrne, John, et al.. (2004). Warfarin skin necrosis associated with protein S deficiency and a mutation in the methylenetetrahydrofolate reductase gene. Clinical and Experimental Dermatology. 29(1). 35–36. 4 indexed citations

20.

Razak, A.R. Abdul, et al.. (2001). Inspiratory flow limitation during sleep in pre-eclampsia: comparison with normal pregnant and nonpregnant women. European Respiratory Journal. 18(4). 672–676. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact